LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.
The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.